Cowen and Company’s Global Blood Therapeutics, Inc. GBT Stock Holding History

Cowen and Company’s Portfolio GBT Stock Details GBT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,000	Closed	-$40K	–	855
2021 Q4	$40K	Buy	+12,000	New	+$372K	﹤0.01%	459
2020 Q3	–	Sell	-15,000	Closed	-$45K	–	557
2020 Q2	$45K	Sell	15,000 -9,000	-38%	-$617K	0.01%	295
2020 Q1	$11K	Buy	+24,000	New	+$1.61M	﹤0.01%	354

Other funds holding GBT

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Cowen and Company's GBT Position: Q1 2022 in Review

Cowen and Company sold out of Global Blood Therapeutics, Inc. (GBT) in Q1 2022, closing a stake of 2,657 shares — an estimated $78K sold.

Cowen and Company first reported a position in GBT in Q2 2020 and held it in 3 quarters. The position peaked at $862K in Q2 2020. 204 funds tracked by Wall St. Rank hold GBT as of Q1 2022.

Cowen and Company reported no remaining Global Blood Therapeutics, Inc. position as of Q1 2022 after selling out during the quarter.
Cowen and Company sold 2,657 Global Blood Therapeutics, Inc. shares in Q1 2022, an estimated $78K.
Cowen and Company first reported a position in Global Blood Therapeutics, Inc. in Q2 2020 and held it in 3 quarters.
Cowen and Company's Global Blood Therapeutics, Inc. position peaked at $862K in Q2 2020.
204 funds tracked by Wall St. Rank held Global Blood Therapeutics, Inc. as of Q1 2022.

Based on Cowen and Company's 13F filing for Q1 2022, filed 16 May 2022.